Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Private companies for phase I studies?

F Lhoste1

  • 1Service de Pharmacologie Clinique, Hôpital Necker-Enfants Malades, Paris, France.

Fundamental & Clinical Pharmacology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[8th Descartes-Berkeley interuniversity symposium on health economics, May 2013, Paris, France: an overview].

Annales pharmaceutiques francaises·2013
Same author

[Trust-based economics with medicine outcome-based pricing].

Annales pharmaceutiques francaises·2013
Same author

Is uranyl scavenger hexakis(3,6-anhydro) tetrakis(2A,B,D,E-O-octyl) cyclomaltohexaose (OCT) relevant with biosystems?

Bollettino chimico farmaceutico·2001
Same author

1H-NMR study of heavy metals complexation with hexakis(3,6-anhydro) tetrakis(2A,B,D,E-O-octyl) cyclomaltohexaose (OCT).

Bollettino chimico farmaceutico·2001
Same author

[Postoperative analgesia after ligamentoplasty of the knee. Comparison of epidural morphine and intravenous nalbuphine].

Cahiers d'anesthesiologie·1995
Same author

Head injury: clonidine decreases plasma catecholamines.

Critical care medicine·1990
Same journal

Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.

Fundamental & clinical pharmacology·2026
Same journal

TAAR1-Associated Trace Amines for Cutaneous Nociceptive Blockade in Rats.

Fundamental & clinical pharmacology·2026
Same journal

Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.

Fundamental & clinical pharmacology·2026
Same journal

Probucol Exerts Anticancer Effects on SW480 Human Colorectal Cancer Cells via Modulation of Apoptosis- and Angiogenesis-Related Proteins.

Fundamental & clinical pharmacology·2026
Same journal

Nebivolol Protects the Thoracic and Abdominal Aorta and Their Perivascular Adipose Tissue From the Differential Detrimental Effects of Obesity.

Fundamental & clinical pharmacology·2026
Same journal

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Fundamental & clinical pharmacology·2026
See all related articles

Phase I clinical trials in France are debated, with few conducted due to strict definitions. Ensuring volunteer safety and ethical considerations are paramount in these early-stage drug development studies.

Area of Science:

  • Clinical Pharmacology
  • Drug Development
  • Medical Ethics

Background:

  • The location for conducting Phase I clinical trials in France remains a subject of ongoing debate.
  • A strict definition of Phase I studies results in a low annual number of such trials being performed in France.
  • These early-phase studies, typically involving healthy volunteers, necessitate a strong focus on ethical considerations and participant safety.

Purpose of the Study:

  • To explore the ongoing debate in France concerning the appropriate venue for Phase I clinical trials.
  • To highlight the critical importance of ethics and safety in Phase I studies involving healthy volunteers.
  • To examine the foundational elements ensuring safety and ethical conduct in early-phase clinical investigations.

Main Methods:

Related Experiment Videos

  • Analysis of the current regulatory and ethical landscape for Phase I studies in France.
  • Review of the definition and scope of Phase I clinical trials.
  • Examination of the principles underpinning safety and ethical considerations in early-phase research.

    • Main Results:

    • The strict definition of Phase I studies limits their number in France.
    • Investigator independence and a controlled laboratory environment are crucial for ensuring safety.
    • Economic independence of investigators is key to prioritizing volunteer well-being and ethical conduct.

    Conclusions:

    • The current framework for Phase I studies in France requires careful consideration regarding location and definition.
    • Prioritizing investigator independence and a secure laboratory setting are essential for ethical and safe clinical trials.
    • Focusing on the volunteer's personal interest through investigator independence is vital for ethical compliance in Phase I studies.